Teicoplanin is a glycopeptide antibiotic produced by fermentation of Actinoplanes teichomyceticus. It consists of several closely related glycopeptide components, including major teicoplanin A2 components and A3 components. Its antibacterial activity results from inhibition of bacterial cell-wall synthesis.
Teicoplanin is primarily used for the treatment of serious infections caused by susceptible Gram-positive bacteria. It is administered parenterally because it has very limited gastrointestinal absorption.
Teicoplanin is identified by CAS No. 61036-62-2. Unlike conventional APIs with one fixed molecular formula, teicoplanin is a complex mixture of related glycopeptides. PubChem describes five major teicoplanin A2 components and four minor components, all sharing a common glycopeptide core but differing in their side chains.
The Japanese Pharmacopoeia defines teicoplanin as a mixture of glycopeptide substances having antibacterial activity produced by Actinoplanes teichomyceticus. Its potency is expressed as mass of teicoplanin per milligram on an anhydrous, de-sodium-chloride and de-residual-solvents basis.
PubChem reports a representative teicoplanin component at 1879.7 g/mol but specifically notes that commercial teicoplanin is a mixture.
Teicoplanin is used as a glycopeptide antibacterial for serious infections caused by susceptible Gram-positive organisms. It inhibits bacterial cell-wall synthesis by interfering with peptidoglycan formation.
Pharmaceutical applications include formulations for infections such as:
The exact approved indications vary by country and product authorization.
Teicoplanin requires specialized quality control because it is a complex fermentation-derived antibiotic mixture.
The Japanese Pharmacopoeia includes controls for:
The JP monograph specifies a minimum potency of 900 μg/mg, calculated on an anhydrous, de-sodium-chloride and de-residual-solvents basis.
Swapnroop supports pharmaceutical API requirements with quality-focused analytical testing, technical documentation and supply support for pharmaceutical development and manufacturing.
Teicoplanin API can be supported with appropriate specifications, potency testing and batch-specific quality documentation according to the intended pharmaceutical application.
Teicoplanin should be protected from moisture and inappropriate environmental conditions. Packaging should provide suitable protection against contamination and degradation.
Storage conditions should follow the applicable approved API specification and stability data for the supplied batch.
Documentation may include:
Swapnroop focuses on quality-oriented pharmaceutical API solutions supported by analytical testing and technical documentation. Teicoplanin can be supplied according to agreed specifications and customer requirements for pharmaceutical development and manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Heavy Metals | 50 ppm |
| pH (1% Solution) | 6.3–7.7 |
| Total Impurities | NMT 0.2% |
| Water Content | NMT 15.0% |